In AD research, tau acetylation has garnered considerable attention as a notable factor in the development and progression of the disease.[28, 89, 90, 92] Consequently, directing interventions towards the modulation of acetylation machinery presents a promising avenue for therapeutic exploration, with the potential to revolutionize the treatment of AD and ameliorate its neurodegenerative consequences. This evidence concerns the gene MAPT and Alzheimer disease.